Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study

Photodiagnosis and Photodynamic Therapy

Volumn 13, Issue , 2016, Pages 130-138

  Azaïs, Henri ^a   Schmitt, Caroline ^b,c   Tardivel, Meryem ^a   Kerdraon, Olivier ^a   Stallivieri, Aurélie ^d   Frochot, Céline ^d   Betrouni, Nacim ^a   Collinet, Pierre ^a   Mordon, Serge ^a  

^a UNIV LILLE   (France)

^b HÔPITAL LOUIS MOURIER   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Folate receptor; Ovarian peritoneal carcinomatosis; Photodynamic therapy; Photosensitizer; Targeted therapy

Indexed keywords

FOLATE RECEPTOR 1; FOLIC ACID; N [2 [2 (2 AMINOETHOXY)ETHOXY]ETHYL]FOLIC ACID]4 CARBOXYPHENYLPORPHYRIN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMATOSIS; COLON; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; KIDNEY; LIVER; MICROMETASTASIS; NONHUMAN; OVARY; OVARY CARCINOMA; PERITONEUM; PERITONEUM METASTASIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; SMALL INTESTINE; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; FISCHER 344 RAT; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; PHOTOCHEMOTHERAPY; PRECLINICAL STUDY; PROCEDURES; RADIATION RESPONSE; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; FEMALE; FOLATE RECEPTOR 1; FOLIC ACID; INJECTIONS, INTRAPERITONEAL; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS; RATS, INBRED F344; TREATMENT OUTCOME;

EID: 84960499289     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.07.005     Document Type: Article

References (32)

1. Eisenkop S.M., Spirtos N.M., Lin W.-C.M. Optimal cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol. Oncol. 2006, 103(1):329-335.
2. Vergote I., Amant F., Kristensen G., Ehlen T., Reed N.S., Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. Eur. J. Cancer 2011, 47:S88-S92. (Suppl. 3).
3. Al Rawahi T., Lopes A.D., Bristow R.E., Bryant A., Elattar A., Chattopadhyay S., et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst. Rev. 2013, 2:CD008765.
4. Elias D., Goéré D., Dumont F., Honoré C., Dartigues P., Stoclin A., et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur. J. Cancer Oxford Engl. 1990 2014, 50(2):332-340.
5. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J.H., Low P.S., Knutson K.L., et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 2008, 108(3):619-626.
6. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 2000, 41(2):147-162.
7. Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet 2014, 384(9951):1376-1388.
8. Gravier J., Schneider R., Frochot C., Bastogne T., Schmitt F., Didelon J., et al. Improvement of meta-tetra(hydroxyphenyl) chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies. J. Med. Chem. 2008, 51(13):3867-3877.
9. Schneider R., Schmitt F., Frochot C., Fort Y., Lourette N., Guillemin F., et al. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy. Bioorg. Med. Chem. 2005, 13(8):2799-2808.
10. Rose G.S., Tocco L.M., Granger G.A., DiSaia P.J., Hamilton T.C., Santin A.D., et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am. J. Obstet. Gynecol. 1996, 175(3 Pt 1):593-599.
11. Azaïs H., Queniat G., Bonner C., Kerdraon O., Tardivel M., Jetpisbayeva G., et al. Fischer 344 rat: a preclinical model for epithelial ovarian cancer folate-targeted therapy. Int. J. Gynecol. Cancer 2015, (in press). 10.1097/IGC.497.
12. Cengel K.A., Glatstein E., Hahn S.M. Intraperitoneal photodynamic therapy. Cancer Treat Res. 2007, 134:493-514.
13. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 2004, 56(8):1067-1084.
14. Azaïs H., Moussaron A., Khodja Bach S., Bassil A., Betrouni N., Frochot C., et al. FRα: a target for prophylactic photodynamic therapy of ovarian peritoneal metastasis?. Bull. Cancer (Paris) 2014, 101(12):1109-1113.
15. Despierre E., Lambrechts S., Leunen K., Berteloot P., Neven P., Amant F., et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol. Oncol. 2013, 130(1):192-199.
16. Crane L.M.A., Arts H.J.G., Oosten M., Low P.S., Zee A.G.J., Dam G.M., et al. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell. Oncol. 2011, 35(1):9-18.
17. Moret F., Scheglmann D., Reddi E. Folate-targeted PEGylated liposomes improve the selectivity of PDT with meta-tetra(hydroxyphenyl) chlorin (m-THPC). Photochem. Photobiol. Sci. 2013, 12(5):823.
18. Li D., Li P., Lin H., Jiang Z., Guo L., Li B. A novel chlorin-PEG-folate conjugate with higher water solubility, lower cytotoxicity, better tumor targeting and photodynamic activity. J. Photochem. Photobiol. B 2013, 127C:28-37.
19. Naumann R.W., Coleman R.L., Burger R.A., Sausville E.A., Kutarska E., Ghamande S.A., et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 2013 JCO 2013, 49:7685.
20. Razzak M. Gynaecological cancer: vintafolide-targeting the folate receptor with a cytotoxic offers hope. Nat. Rev. Clin. Oncol. 2013, 10(12):668.
21. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005, 338(2):284-293.
22. O'shannessy D.J., Somers E.B., Smale R., Fu Y.-S. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol. 2013, 32(3):258-268.
23. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. 1991, 88(13):5572-5576.
24. Van Dam G.M., Themelis G., Crane L.M.A., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat. Med. 2011, 17(10):1315-1319.
25. Guyon L., Farine M.-O., Lesage J.C., Gevaert A.-M., Simonin S., Schmitt C., et al. Photodynamic therapy of ovarian cancer peritoneal metastasis with hexaminolevulinate: a toxicity study. Photodiagn. Photodyn. Ther. 2014, 11(Sep(3)):265-274.
26. Delaney T.F., Sindelar W.F., Tochner Z., Smith P.D., Friauf W.S., Thomas G., et al. Phase I. study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int. J. Radiat. Oncol. 1993, 25(3):445-457.
27. Sindelar W.F., Sullivan F.J., Abraham E., DeLaney T.F., Smith P.D., Friauf G.F., et al. Intraperitoneal photodynamic therapy shows efficacy in phase I trial. Proc. Am. Soc. Clin. Oncol. 1995, 14:447.
28. Sindelar W.F., DeLaney T.F., Tochner Z., et al. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms: phase i study. Arch. Surg. 1991, 126(3):318-324.
29. Hahn S.M., Fraker D.L., Mick R., Metz J., Busch T.M., Smith D., Phase et al.A. Trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin. Cancer Res. 2006, 12(8):2517-2525.
30. Hendren S.K., Hahn S.M., Spitz F.R., Bauer T.W., Rubin S.C., Zhu T., et al.Phase I.I. trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann. Surg. Oncol. 2001, 8(1):65-71.
31. Canter R.J., Mick R., Kesmodel S.B., Raz D.J., Spitz F.R., Metz J.M., et al. Intraperitoneal photodynamic therapy causes a capillary-leak syndrome. Ann. Surg. Oncol. 2003, 10(5):514-524.
32. Hahn S.M., Putt M.E., Metz J., Shin D.B., Rickter E., Menon C., et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2006, 12(18):5464-5470.